Deacetylated CHITIN, a linear polysaccharide of deacetylated beta-1,4-D-glucosamine. It is used in HYDROGEL and to treat WOUNDS.
A linear polysaccharide of beta-1->4 linked units of ACETYLGLUCOSAMINE. It is the second most abundant biopolymer on earth, found especially in INSECTS and FUNGI. When deacetylated it is called CHITOSAN.
Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.
Nanometer-sized particles that are nanoscale in three dimensions. They include nanocrystaline materials; NANOCAPSULES; METAL NANOPARTICLES; DENDRIMERS, and QUANTUM DOTS. The uses of nanoparticles include DRUG DELIVERY SYSTEMS and cancer targeting and imaging.
Relating to the size of solids.
Term used to designate tetrahydroxy aldehydic acids obtained by oxidation of hexose sugars, i.e. glucuronic acid, galacturonic acid, etc. Historically, the name hexuronic acid was originally given to ascorbic acid.
A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.
Synthetic or natural materials, other than DRUGS, that are used to replace or repair any body TISSUES or bodily function.
Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.
Salts of alginic acid that are extracted from marine kelp and used to make dental impressions and as absorbent material for surgical dressings.
Holmium. An element of the rare earth family of metals. It has the atomic symbol Ho, atomic number 67, and atomic weight 164.93.
A spectroscopic technique in which a range of wavelengths is presented simultaneously with an interferometer and the spectrum is mathematically derived from the pattern thus obtained.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
Dosage forms of a drug that act over a period of time by controlled-release processes or technology.
The preparation, mixing, and assembling of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814)
Nanometer-sized, hollow, spherically-shaped objects that can be utilized to encapsulate small amounts of pharmaceuticals, enzymes, or other catalysts (Glossary of Biotechnology and Nanobiotechnology, 4th ed).
Small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various reagents acting as tags or markers.
The application of scientific knowledge or technology to pharmacy and the pharmaceutical industry. It includes methods, techniques, and instrumentation in the manufacture, preparation, compounding, dispensing, packaging, and storing of drugs and other preparations used in diagnostic and determinative procedures, and in the treatment of patients.

Mode of action of chitin deacetylase from Mucor rouxii on N-acetylchitooligosaccharides. (1/1030)

The mode of action of chitin deacetylase from the fungus Mucor rouxii on N-acetylchitooligosaccharides with a degree of polymerization 1-7 has been elucidated. Identification of the sequence of chitin oligomers following enzymatic deacetylation was verified by the alternative use of two specific exo-glycosidases in conjunction with HPLC. The results were further verified by 1H-NMR spectroscopy. It was observed that the length of the oligomer is important for enzyme action. The enzyme cannot effectively deacetylate chitin oligomers with a degree of polymerization lower than three. Tetra-N-acetylchitotetraose and penta-N-acetylchitopentaose are fully deacetylated by the enzyme, while in the case of tri-N-acetylchitotriose, hexa-N-acetylchitohexaose and hepta-N-acetylchitoheptaose the reducing-end residue always remains intact. Furthermore, the enzyme initially removes an acetyl group from the nonreducing-end residue of all chitin oligomers with a degree of polymerization higher than 2, and further catalyses the hydrolysis of the following acetamido groups in a processive fashion. The results are in agreement with the mode of action that the same enzyme exhibits on partially deacetylated water soluble chitosan polymers.  (+info)

Chs7p, a new protein involved in the control of protein export from the endoplasmic reticulum that is specifically engaged in the regulation of chitin synthesis in Saccharomyces cerevisiae. (2/1030)

The Saccharomyces cerevisiae CHS7 gene encodes an integral membrane protein located in the ER which is directly involved in chitin synthesis through the regulation of chitin synthase III (CSIII) activity. In the absence of CHS7 product, Chs3p, but not other secreted proteins, is retained in the ER, leading to a severe defect in CSIII activity and consequently, to a reduced rate of chitin synthesis. In addition, chs7 null mutants show the yeast phenotypes associated with a lack of chitin: reduced mating efficiency and lack of the chitosan ascospore layer, clear indications of Chs7p function throughout the S. cerevisiae biological cycle. CHS3 overexpression does not lead to increased levels of CSIII because the Chs3p excess is retained in the ER. However, joint overexpression of CHS3 and CHS7 increases the export of Chs3p from the ER and this is accompanied by a concomitant increase in CSIII activity, indicating that the amount of Chs7p is a limiting factor for CSIII activity. Accordingly, CHS7 transcription is increased when elevated amounts of chitin synthesis are detected. These results show that Chs7p forms part of a new mechanism specifically involved in Chs3p export from the ER and consequently, in the regulation of CSIII activity.  (+info)

Modification of chitosan to improve its hypocholesterolemic capacity. (3/1030)

Cholestyramine is the most widely used bile acid sequestrant in the treatment of hypercholesterolemia. However, cholestyramine has unpleasant side effects as a consequence of its hydrophobic backbone. Therefore, high-capacity bile acid sequestering biopolymers with cationic chitosan derivatives were developed, because electrostatic interactions are important for binding with bile acid anions. Dialkylaminoalkylation and reductive amination of chitosan were done to add dialkylaminoalkyl and an additional free amino group at a hydroxyl site in the chitosan backbone respectively and the amino-derivatized chitosan derivatives were quaternized with methyl iodide to produce a cationic polyelectrolyte. The in vitro bile acid binding capacity of the chitosan derivatives in aqueous NaCl was measured by reversed-phase HPLC. The binding capacities of sodium glycocholate (a major bile acid) to chitosan, DEAE-chitosan, quaternized DEAE-chitosan, and cholestyramine were 1.42, 3.12, 4.06, and 2.78 mmol/g resin, respectively. With quaternized DEAE-chitosan, the bile acid binding capacity increased approximately 50% over that of cholestyramine. The bile acid binding capacity of dialkylaminoalkyl chitosan derivatives increased with the number of carbons in the alkyl groups, indicating that hydrophobic interaction is a secondary factor for the sequestration of bile acids.  (+info)

Development of bacterial contamination during production of yeast extracts. (4/1030)

Baker's yeast suspensions having bacterial populations of 10(6) and 10(8) CFU/ml were subjected to autolysis processes designed to obtain yeast extracts (YE). The bacterial contaminants added to the yeast cell suspensions were produced with spent broths obtained from a commercial yeast production plant and contained 59% cocci (Leuconostoc, Aerococcus, Lactococcus) as well as 41% bacilli (Bacillus). Autolyses were conducted at four different pH levels (4.0, 5.5, 7.0, and 8.5) and with two autolysis-promoting agents (ethyl acetate and chitosan). Processing parameters were more important than the initial bacterial population in the development of contaminating bacteria during manufacture of YE. Drops in the viable bacterial population after a 24-h autolysis were observed when pH was adjusted to 4.0 or when ethyl acetate was added. A significant interaction was found between the effects of pH and autolysis promoters on the bacterial population in YE, indicating that the activity of ethyl acetate, as opposed to that of chitosan, was not influenced by pH.  (+info)

Oligogalacturonic acid and chitosan reduce stomatal aperture by inducing the evolution of reactive oxygen species from guard cells of tomato and Commelina communis. (5/1030)

Stomatal opening provides access to inner leaf tissues for many plant pathogens, so narrowing stomatal apertures may be advantageous for plant defense. We investigated how guard cells respond to elicitors that can be generated from cell walls of plants or pathogens during pathogen infection. The effect of oligogalacturonic acid (OGA), a degradation product of the plant cell wall, and chitosan (beta-1,4-linked glucosamine), a component of the fungal cell wall, on stomatal movements were examined in leaf epidermis of tomato (Lycopersicon esculentum L.) and Commelina communis L. These elicitors reduced the size of the stomatal aperture. OGA not only inhibited light-induced stomatal opening, but also accelerated stomatal closing in both species; chitosan inhibited light-induced stomatal opening in tomato epidermis. The effects of OGA and chitosan were suppressed when EGTA, catalase, or ascorbic acid was present in the medium, suggesting that Ca(2+) and H(2)O(2) mediate the elicitor-induced decrease of stomatal apertures. We show that the H(2)O(2) that is involved in this process is produced by guard cells in response to elicitors. Our results suggest that guard cells infected by pathogens may close their stomata via a pathway involving H(2)O(2) production, thus interfering with the continuous invasion of pathogens through the stomatal pores.  (+info)

Maintenance of CD34 expression during proliferation of CD34+ cord blood cells on glycosaminoglycan surfaces. (6/1030)

Recent studies have indicated that glycosaminoglycan (GAG) interactions with hematopoietic progenitors play a significant role in the regulation of hematopoiesis. However, the details of these interactions are not clear. In this study, we examined the role of soluble and immobilized GAGs in the proliferation of CD34+ cells. Chitosan, a cationic polysaccharide, was used to immobilize GAGs in ionic complex membranes. The GAGs studied were heparin, hyaluronate, and chondroitin sulfates A, B, and C. CD34-enriched umbilical cord blood cells were seeded onto tissue culture plates coated with the GAG-chitosan complex membranes. Cultures were maintained in medium supplemented with stem cell factor and interleukin 3 for up to six weeks, during which total and CD34+ cell numbers were determined by flow cytometry. Total cell number expansion ranged from 25-fold to 40-fold after six weeks. However, only heparin and chondroitin sulfate B (CSB) surfaces retained a significant CD34+ fraction. All other surfaces exhibited declines in CD34 expression, with negligible CD34+ percentages remaining after four weeks. In contrast, heparin and CSB surfaces exhibited CD34+ fractions as high as 90% after four weeks. GAG desorption studies indicated that the observed effects were partly mediated by desorbed GAGs in a concentration dependent manner. Subsequent studies showed that sustained high (160 microg/ml) heparin levels had toxic effects, while the same concentration of CSB exhibited more rapid early proliferation of CD34+ cells. In conclusion, this culture system has demonstrated the ability to produce simultaneous proliferation and CD34+ cell enrichment of a partially purified cord blood population by controlling the nature and levels of GAG moieties to which the cells are exposed. The results indicate that specific GAGs can significantly influence the growth and differentiation characteristics of cultured CD34+ cells.  (+info)

Purification, characterization, and gene analysis of a chitosanase (ChoA) from Matsuebacter chitosanotabidus 3001. (7/1030)

The extracellular chitosanase (34,000 M(r)) produced by a novel gram-negative bacterium Matsuebacter chitosanotabidus 3001 was purified. The optimal pH of this chitosanase was 4.0, and the optimal temperature was between 30 and 40 degrees C. The purified chitosanase was most active on 90% deacetylated colloidal chitosan and glycol chitosan, both of which were hydrolyzed in an endosplitting manner, but this did not hydrolyze chitin, cellulose, or their derivatives. Among potential inhibitors, the purified chitosanase was only inhibited by Ag(+). Internal amino acid sequences of the purified chitosanase were obtained. A PCR fragment corresponding to one of these amino acid sequences was then used to screen a genomic library for the entire choA gene encoding chitosanase. Sequencing of the choA gene revealed an open reading frame encoding a 391-amino-acid protein. The N-terminal amino acid sequence had an excretion signal, but the sequence did not show any significant homology to other proteins, including known chitosanases. The 80-amino-acid excretion signal of ChoA fused to green fluorescent protein was functional in Escherichia coli. Taken together, these results suggest that we have identified a novel, previously unreported chitosanase.  (+info)

Characterization of a novel, antifungal, chitin-binding protein from Streptomyces tendae Tu901 that interferes with growth polarity. (8/1030)

The afp1 gene, which encodes the antifungal protein AFP1, was cloned from nikkomycin-producing Streptomyces tendae Tu901, using a nikkomycin-negative mutant as a host and screening transformants for antifungal activity against Paecilomyces variotii in agar diffusion assays. The 384-bp afp1 gene has a low G+C content (63%) and a transcription termination structure with a poly(T) region, unusual attributes for Streptomyces genes. AFP1 was purified from culture filtrate of S. tendae carrying the afp1 gene on the multicopy plasmid pIJ699. The purified protein had a molecular mass of 9,862 Da and lacked a 42-residue N-terminal peptide deduced from the nucleotide sequence. AFP1 was stable at extreme pH values and high temperatures and toward commercial proteinases. AFP1 had limited similarity to cellulose-binding domains of microbial plant cell wall hydrolases and bound to crab shell chitin, chitosan, and cell walls of P. variotii but showed no enzyme activity. The biological activity of AFP1, which represents the first chitin-binding protein from bacteria exhibiting antifungal activity, was directed against specific ascomycetes, and synergistic interaction with the chitin synthetase inhibitor nikkomycin inhibited growth of Aspergillus species. Microscopy studies revealed that fluorescein-labeled AFP1 strongly bound to the surface of germinated conidia and to tips of growing hyphae, causing severe alterations in cell morphogenesis that gave rise to large spherical conidia and/or swollen hyphae and to atypical branching.  (+info)

Chitosan is a complex carbohydrate that is derived from the exoskeletons of crustaceans, such as shrimp and crabs. It is made up of chains of N-acetyl-d-glucosamine and d-glucosamine units. Chitosan has been studied for its potential medical and health benefits, including its ability to lower cholesterol levels, promote weight loss, and help control blood sugar levels. It is also used in wound care products due to its antibacterial and absorbent properties. However, more research is needed to confirm these potential benefits and establish recommended dosages and safety guidelines.

Chitin is a long-chain polymer of N-acetylglucosamine, which is a derivative of glucose. It is a structural component found in the exoskeletons of arthropods such as insects and crustaceans, as well as in the cell walls of fungi and certain algae. Chitin is similar to cellulose in structure and is one of the most abundant natural biopolymers on Earth. It has a variety of industrial and biomedical applications due to its unique properties, including biocompatibility, biodegradability, and adsorption capacity.

A drug carrier, also known as a drug delivery system or vector, is a vehicle that transports a pharmaceutical compound to a specific site in the body. The main purpose of using drug carriers is to improve the efficacy and safety of drugs by enhancing their solubility, stability, bioavailability, and targeted delivery, while minimizing unwanted side effects.

Drug carriers can be made up of various materials, including natural or synthetic polymers, lipids, inorganic nanoparticles, or even cells and viruses. They can encapsulate, adsorb, or conjugate drugs through different mechanisms, such as physical entrapment, electrostatic interaction, or covalent bonding.

Some common types of drug carriers include:

1. Liposomes: spherical vesicles composed of one or more lipid bilayers that can encapsulate hydrophilic and hydrophobic drugs.
2. Polymeric nanoparticles: tiny particles made of biodegradable polymers that can protect drugs from degradation and enhance their accumulation in target tissues.
3. Dendrimers: highly branched macromolecules with a well-defined structure and size that can carry multiple drug molecules and facilitate their release.
4. Micelles: self-assembled structures formed by amphiphilic block copolymers that can solubilize hydrophobic drugs in water.
5. Inorganic nanoparticles: such as gold, silver, or iron oxide nanoparticles, that can be functionalized with drugs and targeting ligands for diagnostic and therapeutic applications.
6. Cell-based carriers: living cells, such as red blood cells, stem cells, or immune cells, that can be loaded with drugs and used to deliver them to specific sites in the body.
7. Viral vectors: modified viruses that can infect cells and introduce genetic material encoding therapeutic proteins or RNA interference molecules.

The choice of drug carrier depends on various factors, such as the physicochemical properties of the drug, the route of administration, the target site, and the desired pharmacokinetics and biodistribution. Therefore, selecting an appropriate drug carrier is crucial for achieving optimal therapeutic outcomes and minimizing side effects.

Nanoparticles are defined in the field of medicine as tiny particles that have at least one dimension between 1 to 100 nanometers (nm). They are increasingly being used in various medical applications such as drug delivery, diagnostics, and therapeutics. Due to their small size, nanoparticles can penetrate cells, tissues, and organs more efficiently than larger particles, making them ideal for targeted drug delivery and imaging.

Nanoparticles can be made from a variety of materials including metals, polymers, lipids, and dendrimers. The physical and chemical properties of nanoparticles, such as size, shape, charge, and surface chemistry, can greatly affect their behavior in biological systems and their potential medical applications.

It is important to note that the use of nanoparticles in medicine is still a relatively new field, and there are ongoing studies to better understand their safety and efficacy.

In the context of medical and health sciences, particle size generally refers to the diameter or dimension of particles, which can be in the form of solid particles, droplets, or aerosols. These particles may include airborne pollutants, pharmaceutical drugs, or medical devices such as nanoparticles used in drug delivery systems.

Particle size is an important factor to consider in various medical applications because it can affect the behavior and interactions of particles with biological systems. For example, smaller particle sizes can lead to greater absorption and distribution throughout the body, while larger particle sizes may be filtered out by the body's natural defense mechanisms. Therefore, understanding particle size and its implications is crucial for optimizing the safety and efficacy of medical treatments and interventions.

Hexuronic acids are a type of uronic acid that contains six carbon atoms and is commonly found in various biological tissues and polysaccharides, such as pectins, heparin, and certain glycoproteins. The most common hexuronic acids are glucuronic acid and iduronic acid, which are formed from the oxidation of the corresponding hexoses, glucose and galactose, respectively. Hexuronic acids play important roles in various biological processes, including the detoxification and excretion of xenobiotics, the formation of proteoglycans, and the regulation of cell growth and differentiation.

Glucuronic acid is a physiological important organic acid, which is a derivative of glucose. It is formed by the oxidation of the primary alcohol group of glucose to form a carboxyl group at the sixth position. Glucuronic acid plays a crucial role in the detoxification process in the body as it conjugates with toxic substances, making them water-soluble and facilitating their excretion through urine or bile. This process is known as glucuronidation. It is also a component of various polysaccharides, such as heparan sulfate and chondroitin sulfate, which are found in the extracellular matrix of connective tissues.

Biocompatible materials are non-toxic and non-reacting substances that can be used in medical devices, tissue engineering, and drug delivery systems without causing harm or adverse reactions to living tissues or organs. These materials are designed to mimic the properties of natural tissues and are able to integrate with biological systems without being rejected by the body's immune system.

Biocompatible materials can be made from a variety of substances, including metals, ceramics, polymers, and composites. The specific properties of these materials, such as their mechanical strength, flexibility, and biodegradability, are carefully selected to meet the requirements of their intended medical application.

Examples of biocompatible materials include titanium used in dental implants and joint replacements, polyethylene used in artificial hips, and hydrogels used in contact lenses and drug delivery systems. The use of biocompatible materials has revolutionized modern medicine by enabling the development of advanced medical technologies that can improve patient outcomes and quality of life.

Pharmaceutical chemistry is a branch of chemistry that deals with the design, synthesis, and development of chemical entities used as medications. It involves the study of drugs' physical, chemical, and biological properties, as well as their interactions with living organisms. This field also encompasses understanding the absorption, distribution, metabolism, and excretion (ADME) of drugs in the body, which are critical factors in drug design and development. Pharmaceutical chemists often work closely with biologists, medical professionals, and engineers to develop new medications and improve existing ones.

Alginates are a type of polysaccharide derived from brown algae or produced synthetically, which have gelling and thickening properties. In medical context, they are commonly used as a component in wound dressings, dental impressions, and bowel cleansing products. The gels formed by alginates can provide a protective barrier to wounds, help maintain a moist environment, and promote healing. They can also be used to create a mold of the mouth or other body parts in dental and medical applications. In bowel cleansing, sodium alginates are often combined with sodium bicarbonate and water to form a solution that expands and stimulates bowel movements, helping to prepare the colon for procedures such as colonoscopy.

Holmium is a chemical element with the symbol Ho and atomic number 67. It's a rare earth metal that belongs to the lanthanide series. In the field of medicine, holmium is used in the form of holmium oxide (HoO) as a component in some medical devices, particularly in laser surgery.

The Holmium:Yttrium-Aluminum-Garnet (Ho:YAG) laser is commonly used in urology for the treatment of kidney stones and various urological conditions. The holmium laser emits light at a wavelength of 2100 nanometers, which is highly absorbed by water and tissue, making it an effective tool for cutting and coagulating tissues with minimal thermal damage to surrounding areas.

It's important to note that direct medical applications of holmium as an element are not common, but rather its use in the form of compounds or medical devices is more prevalent.

Fourier Transform Infrared (FTIR) spectroscopy is a type of infrared spectroscopy that uses the Fourier transform mathematical technique to convert the raw data obtained from an interferometer into a more interpretable spectrum. This technique allows for the simultaneous collection of a wide range of wavelengths, resulting in increased sensitivity and speed compared to traditional dispersive infrared spectroscopy.

FTIR spectroscopy measures the absorption or transmission of infrared radiation by a sample as a function of frequency, providing information about the vibrational modes of the molecules present in the sample. This can be used for identification and quantification of chemical compounds, analysis of molecular structure, and investigation of chemical interactions and reactions.

In summary, FTIR spectroscopy is a powerful analytical technique that uses infrared radiation to study the vibrational properties of molecules, with increased sensitivity and speed due to the use of Fourier transform mathematical techniques and an interferometer.

Drug delivery systems (DDS) refer to techniques or technologies that are designed to improve the administration of a pharmaceutical compound in terms of its efficiency, safety, and efficacy. A DDS can modify the drug release profile, target the drug to specific cells or tissues, protect the drug from degradation, and reduce side effects.

The goal of a DDS is to optimize the bioavailability of a drug, which is the amount of the drug that reaches the systemic circulation and is available at the site of action. This can be achieved through various approaches, such as encapsulating the drug in a nanoparticle or attaching it to a biomolecule that targets specific cells or tissues.

Some examples of DDS include:

1. Controlled release systems: These systems are designed to release the drug at a controlled rate over an extended period, reducing the frequency of dosing and improving patient compliance.
2. Targeted delivery systems: These systems use biomolecules such as antibodies or ligands to target the drug to specific cells or tissues, increasing its efficacy and reducing side effects.
3. Nanoparticle-based delivery systems: These systems use nanoparticles made of polymers, lipids, or inorganic materials to encapsulate the drug and protect it from degradation, improve its solubility, and target it to specific cells or tissues.
4. Biodegradable implants: These are small devices that can be implanted under the skin or into body cavities to deliver drugs over an extended period. They can be made of biodegradable materials that gradually break down and release the drug.
5. Inhalation delivery systems: These systems use inhalers or nebulizers to deliver drugs directly to the lungs, bypassing the digestive system and improving bioavailability.

Overall, DDS play a critical role in modern pharmaceutical research and development, enabling the creation of new drugs with improved efficacy, safety, and patient compliance.

I couldn't find a medical definition specifically for "delayed-action preparations." However, in the context of pharmacology, it may refer to medications or treatments that have a delayed onset of action. These are designed to release the active drug slowly over an extended period, which can help to maintain a consistent level of the medication in the body and reduce the frequency of dosing.

Examples of delayed-action preparations include:

1. Extended-release (ER) or controlled-release (CR) formulations: These are designed to release the drug slowly over several hours, reducing the need for frequent dosing. Examples include extended-release tablets and capsules.
2. Transdermal patches: These deliver medication through the skin and can provide a steady rate of drug delivery over several days. Examples include nicotine patches for smoking cessation or fentanyl patches for pain management.
3. Injectable depots: These are long-acting injectable formulations that slowly release the drug into the body over weeks to months. An example is the use of long-acting antipsychotic injections for the treatment of schizophrenia.
4. Implantable devices: These are small, biocompatible devices placed under the skin or within a body cavity that release a steady dose of medication over an extended period. Examples include hormonal implants for birth control or drug-eluting stents used in cardiovascular procedures.

Delayed-action preparations can improve patient compliance and quality of life by reducing dosing frequency, minimizing side effects, and maintaining consistent therapeutic levels.

Drug compounding is the process of combining, mixing, or altering ingredients to create a customized medication to meet the specific needs of an individual patient. This can be done for a variety of reasons, such as when a patient has an allergy to a certain ingredient in a mass-produced medication, or when a patient requires a different dosage or formulation than what is available commercially.

Compounding requires specialized training and equipment, and compounding pharmacists must follow strict guidelines to ensure the safety and efficacy of the medications they produce. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA), but the FDA does regulate the ingredients used in compounding and has oversight over the practices of compounding pharmacies.

It's important to note that while compounding can provide benefits for some patients, it also carries risks, such as the potential for contamination or incorrect dosing. Patients should only receive compounded medications from reputable pharmacies that follow proper compounding standards and procedures.

A nanocapsule is a type of nanoparticle that is characterized by its hollow, spherical structure. It is composed of a polymeric membrane that encapsulates an inner core or "cargo" which can be made up of various substances such as drugs, proteins, or imaging agents. The small size of nanocapsules (typically ranging from 10 to 1000 nanometers in diameter) allows them to penetrate cells and tissue more efficiently than larger particles, making them useful for targeted drug delivery and diagnostic applications.

The polymeric membrane can be designed to be biodegradable or non-biodegradable, depending on the desired application. Additionally, the surface of nanocapsules can be functionalized with various moieties such as antibodies, peptides, or small molecules to enhance their targeting capabilities and improve their stability in biological environments.

Overall, nanocapsules have great potential for use in a variety of medical applications, including cancer therapy, gene delivery, and vaccine development.

Microspheres are tiny, spherical particles that range in size from 1 to 1000 micrometers in diameter. They are made of biocompatible and biodegradable materials such as polymers, glass, or ceramics. In medical terms, microspheres have various applications, including drug delivery systems, medical imaging, and tissue engineering.

In drug delivery, microspheres can be used to encapsulate drugs and release them slowly over time, improving the efficacy of the treatment while reducing side effects. They can also be used for targeted drug delivery, where the microspheres are designed to accumulate in specific tissues or organs.

In medical imaging, microspheres can be labeled with radioactive isotopes or magnetic materials and used as contrast agents to enhance the visibility of tissues or organs during imaging procedures such as X-ray, CT, MRI, or PET scans.

In tissue engineering, microspheres can serve as a scaffold for cell growth and differentiation, promoting the regeneration of damaged tissues or organs. Overall, microspheres have great potential in various medical applications due to their unique properties and versatility.

Medical technology, also known as health technology, refers to the use of medical devices, medicines, vaccines, procedures, and systems for the purpose of preventing, diagnosing, or treating disease and disability. This can include a wide range of products and services, from simple devices like tongue depressors and bandages, to complex technologies like MRI machines and artificial organs.

Pharmaceutical technology, on the other hand, specifically refers to the application of engineering and scientific principles to the development, production, and control of pharmaceutical drugs and medical devices. This can include the design and construction of manufacturing facilities, the development of new drug delivery systems, and the implementation of quality control measures to ensure the safety and efficacy of pharmaceutical products.

Both medical technology and pharmaceutical technology play crucial roles in modern healthcare, helping to improve patient outcomes, reduce healthcare costs, and enhance the overall quality of life for individuals around the world.

No FAQ available that match "chitosan"

No images available that match "chitosan"